In regard to other ADC targets, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is highly expressed in about 25% of lung cancers, and a novel ADC targeting this is tusamitamab ravtansine, comprising a humanized monoclonal antibody and a cytotoxic maytansinoid, DM4. The gene discussed is CEACAM5; the disease is lung cancer.